Indeed, these results are in agreement with the observation that the efficacy of TMZ in glioma cells is cell cycle dependent, since E2F expression in glioma cells increases TMZ sensitivity, whereas p21cip1 expression reduces it [19]. The gene discussed is CDKN1A; the disease is glioma.